BLCO Company Profile and Key Details

Q: Who are the executives of BLCO?

Mr. Brenton L. Saunders J.D.Executive ChairmanMr. A. Robert D. BaileyExecutive Vice President & Chief Legal OfficerMr. Andrew StewartPres of PharmaceuticalsMr. Luc BonnefoyPres of SurgicalDr. Louis W. YuExecutive Vice President & Chief Quality OfficerMr. Dennis AsharinExecutive Vice President, Head of Quality, Chief Global Manufacturing & Supply Chain OfficerMr. John FerrisExecutive Vice President of ConsumerMr. Jonathon L. KellermanChief Compliance OfficerT.J. CrawfordChief Communications OfficerDr. Manisha A. Narasimhan Ph.D.Chief Corporation Devel. & Digital OfficerMs. Asli GevgililiChief HR OfficerMr. Frederick J. MunschSenior Vice PresidentDr. Yehia Hashad M.D.Executive Vice President of R&D and Chief Medical officerMr. Joseph C. PapaChief Executive Officer & DirectorMr. Joseph F. GordonPres of Global Consumer, Surgical & Vision CareMr. Osama A. EldessoukyExecutive Vice President & Chief Financial OfficerMr. Louis W. YuExecutive Vice President & Chief Quality OfficerMs. Christina M. AckermannExecutive Vice President, Gen. Counsel & Pres of Ophthalmic PharmaceuticalsMs. Kelly WebberExecutive Vice President & Chief HR OfficerLuc BonnefoySenior Vice President of Surgical

NYSE : BLCO

Bausch + Lomb

$16.99

0.01+0.06%

Open: 2:56 PM

73.49

B+ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Bausch + Lomb Corporation (BLCO) stock surged +0.06%, trading at $16.99 on NYSE, up from the previous close of $16.98. The stock opened at $16.88, fluctuating between $16.88 and $17.07 in the recent session.

Stock Snapshot

16.98

Prev. Close

6.02B

Market Cap

16.875

Day Low

-19.76

P/E Ratio

-0.86

EPS (TTM)

-0.56

Cash Flow per Share

16.88

Open

354.19M

Number of Shares

17.07

Day High

10.31%

Free Float in %

19.53

Book Value

137.07K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 19, 2025	16.81	17.18	16.80	16.98	462.38K
Dec 17, 2025	16.90	17.06	16.79	16.88	347.61K
Dec 16, 2025	17.33	17.33	16.84	16.98	399.06K
Dec 15, 2025	17.04	17.10	16.83	17.09	385.52K
Dec 12, 2025	17.33	17.33	16.86	16.99	440.47K
Dec 11, 2025	17.15	17.41	17.04	17.27	687.78K
Dec 10, 2025	16.40	16.95	16.40	16.73	439.13K
Dec 09, 2025	16.51	16.70	16.39	16.46	158.88K
Dec 08, 2025	16.81	16.86	16.47	16.56	290.48K
Dec 05, 2025	17.00	17.35	16.82	16.82	234.39K
Dec 04, 2025	16.80	17.15	16.80	16.81	172K
Dec 03, 2025	17.05	17.10	16.73	16.96	454.76K
Dec 02, 2025	17.63	17.70	16.82	17.05	666.37K
Dec 01, 2025	16.10	16.75	16.03	16.56	390.69K
Nov 28, 2025	16.23	16.34	16.18	16.19	119.49K
Nov 26, 2025	15.99	16.22	15.93	16.20	197.12K
Nov 25, 2025	15.46	15.98	15.46	15.89	244.44K
Nov 24, 2025	15.08	15.59	15.08	15.45	243.81K
Nov 21, 2025	14.57	15.33	14.54	15.07	403.23K
Nov 20, 2025	14.75	14.79	14.44	14.56	342.49K

Contact Details

Vaughan, ON L4K 4B4

Canada

https://www.bausch.com 905 695 7700

About Company

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.

Stock Peers

WST

3.88+1.44%

West Pharmaceutical Services, Inc.$272.54 RMD

2.39+0.99%

ResMed Inc.$244.94 BDX

0.89+0.46%

Becton, Dickinson and Company$195.59 TFX

-2.61-2.10%

Teleflex Incorporated$121.89 ATR

-1.23-1.00%

AptarGroup, Inc.$121.39 HAE

0.31+0.39%

Haemonetics Corporation$80.21 ALC

0.475+0.60%

Alcon Inc.$79.97 WRBY

-0.34-1.27%

Warby Parker Inc.$26.39 STVN

0.01+0.05%

Stevanato Group S.p.A.$20.53 BAX

-0.11-0.58%

Baxter International Inc.$18.96

Company Overview

Bausch + Lomb Corporation (NYSE:BLCO) closed at $16.99 USD, gaining $0.01 (0.06%) from the previous close of $16.98. The stock is currently mid-range between its 52-week high and low $10.45 and $18.55. With a market capitalization of about $6.02 billion, Bausch + Lomb Corporation is classified as a mid-cap and shows lower-than-market volatility (beta ~0.62). Key stats such as the average daily volume over the past year has been around 474.90 thousand shares, volume is running light vs its 52-week average. Headquartered in Vaughan, ON, Bausch + Lomb Corporation operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Brenton L. Saunders, the company employs approximately 13,500 people and listed since May 06, 2022. Bausch + Lomb Corporation operates as an eye health company worldwide.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 2.34%, SMA50 7.18%, SMA200 20.18%). The stock’s 14-day RSI is 59.85 (neutral), while the ATR of 0.47 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -8.48% below its high and over 62.49% above its low. Average 10-day trading volume of 407.01 thousand shares is below the 3-month average of 468.48 thousand, indicating normal recent market interest.

Valuation Metrics

Bausch + Lomb Corporation trades at a P/E ratio of -19.72, slightly below the S&P 500 average, with a price-to-sales ratio of 1.21 and a price-to-book ratio of 0.94 suggesting the stock is closer to book value. The P/FCF stands at -30.68, also below market averages.

Dividend & Fair Value

Bausch + Lomb Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $12.70. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 18.9% annually over the next five years. The latest quarter delivered EPS of -$0.08. The next quarter is forecast at $0.36. Next year's EPS is expected at -$4.37. Analyst sentiment is neutral. Analyst rating data shows there are 10 Strong Buy ratings, 4 Buy ratings, 11 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $24.00 to $13.00. The high target offers 41.34% upside. The low target suggests -23.44% downside. The mean target is $17.58. This offers 3.53% upside. Bausch + Lomb Corporation earnings surprise history is a mixed track record. The quarter that ended October 29, 2025, missed forecasts by -149.41%. The prior quarter beat by 16.67%. Over the last six quarters, Apple has recorded several small beats. These include -430.17% in July 31, 2024.

Shareholding & Insider Activity

Bausch + Lomb Corporation has 353.87 million shares outstanding. The public float is 42.13 million shares, elevated short interest at 7.58% of float. This equals 3.23 million shares. The short ratio is 3.9 days. Institutional investors hold 94.57% of the float. Insiders own 88.06%. Bausch Health Companies Inc. holds 310.45 million shares, SAUNDERS BRENT L has 719.16 thousand shares and VON ESCHENBACH ANDREW C. has 41.75 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Bausch + Lomb generated $4.15B in revenue, or $11.83 per share. Gross margin was 60.40%, operating margin 3.14%, and net profit margin -6.27%. Returns are negative, with ROA at -1.93% and ROE at -3.80%.
On valuation metrics, Bausch + Lomb trades at a P/E of -19.72, P/S of 1.21 and P/B of 0.94. The current ratio is 1.51 and quick ratio is 0.98. Operationally, the company’s inventory turnover is 2.01 and cash conversion cycle is 190.58 days. Debt-to-equity is 0.77, supported by a cash flow-to-debt ratio of 0.03.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Bausch + Lomb posted revenue of $4.15B, down slightly from $3.77B in the prior quarter. Gross profit was $2.50B (margin 60.40%). Operating income was $130.00M (margin 3.1%). Net income was- $260.00M (EPS - $0.74).
The company ended the quarter with $331.00M in cash and short-term investments, a total debt of $4.56B, and net debt of $4.23B. Total assets were $13.44B, with equity of $6.92B. Financials further reflected weakness, with operating cash flow of - $17.00M, free cash flow of - $198.00M, and capital expenditures of - $181.00M.

Price Forecast & Outlook

Our AI price prediction model suggests that Bausch + Lomb Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.12%, with price expected at $17.85 by January 02, 2026, within a range of $17.31 to $18.39 3-Month Outlook: Projected fall of -0.82%, reaching $16.84 by March 19, 2026, with a range of $15.90 to $17.73. 1-Year Outlook: Projected loss of -11.78%, with price at $14.98 by December 18, 2026, within a range of $14.28 to $15.73.

Key Takeaways

Bausch + Lomb Corporation (NYSE:BLCO) shares are flat -5.98% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Bausch + Lomb Corporation trading at a premium to the broader market with a P/E of -19.72. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $19.16, suggesting 12.84% upside. Our AI forecast model points to short-term strength (5.12% over two weeks), a medium-term fall (-0.82% over three months), and a longer-term loss (-11.78% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Bausch + Lomb Corporation (BLCO) stock price?

Bausch + Lomb Corporation (NYSE: BLCO) stock price is $16.99 in the last trading session. During the trading session, BLCO stock reached the peak price of $17.07 while $16.88 was the lowest point it dropped to. The percentage change in BLCO stock occurred in the recent session was 0.06% while the dollar amount for the price change in BLCO stock was $0.01.

BLCO's industry and sector of operation?

The NYSE listed BLCO is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector. Bausch + Lomb Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of BLCO?

Mr. Brenton L. Saunders J.D.
Executive Chairman
Mr. A. Robert D. Bailey
Executive Vice President & Chief Legal Officer
Mr. Andrew Stewart
Pres of Pharmaceuticals
Mr. Luc Bonnefoy
Pres of Surgical
Dr. Louis W. Yu
Executive Vice President & Chief Quality Officer
Mr. Dennis Asharin
Executive Vice President, Head of Quality, Chief Global Manufacturing & Supply Chain Officer
Mr. John Ferris
Executive Vice President of Consumer
Mr. Jonathon L. Kellerman
Chief Compliance Officer
T.J. Crawford
Chief Communications Officer
Dr. Manisha A. Narasimhan Ph.D.
Chief Corporation Devel. & Digital Officer
Ms. Asli Gevgilili
Chief HR Officer
Mr. Frederick J. Munsch
Senior Vice President
Dr. Yehia Hashad M.D.
Executive Vice President of R&D and Chief Medical officer
Mr. Joseph C. Papa
Chief Executive Officer & Director
Mr. Joseph F. Gordon
Pres of Global Consumer, Surgical & Vision Care
Mr. Osama A. Eldessouky
Executive Vice President & Chief Financial Officer
Mr. Louis W. Yu
Executive Vice President & Chief Quality Officer
Ms. Christina M. Ackermann
Executive Vice President, Gen. Counsel & Pres of Ophthalmic Pharmaceuticals
Ms. Kelly Webber
Executive Vice President & Chief HR Officer
Luc Bonnefoy
Senior Vice President of Surgical

How BLCO did perform over past 52-week?

BLCO's closing price is 62.49% higher than its 52-week low of $10.45 where as its distance from 52-week high of $18.55 is -8.48%.

How many employees does BLCO have?

Number of BLCO employees currently stands at 13,500.

Link for BLCO official website?

Official Website of BLCO is: https://www.bausch.com

How do I contact BLCO?

BLCO could be contacted at phone 905 695 7700 and can also be accessed through its website. BLCO operates from 520 Applewood Crescent, Vaughan, ON L4K 4B4, Canada.

How many shares of BLCO are traded daily?

BLCO stock volume for the day was 137.07K shares. The average number of BLCO shares traded daily for last 3 months was 474.9K.

What is the market cap of BLCO currently?

The market value of BLCO currently stands at $6.02B with its latest stock price at $16.99 and 354.19M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	13500
Beta	0.62
Sales or Revenue	$4.15B
5Y Sales Change%	0.13%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Instruments & Supplies

BLCO Company Profile and Key Details

Bausch + Lomb

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Dividend & Fair Value

Shareholding & Insider Activity

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Technical Performance

Earnings & Analyst Outlook

Key Takeaways

Price Forecast & Outlook

Valuation Metrics